S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
NASDAQ:ZEAL

Zealand Pharma A/S Stock Forecast, Price & News

$37.61
+0.01 (+0.03 %)
(As of 01/15/2021 08:00 PM ET)
Add
Compare
Today's Range
$37.61
Now: $37.61
$37.61
50-Day Range
$34.47
MA: $36.83
$38.75
52-Week Range
$22.00
Now: $37.61
$44.60
Volume1,800 shs
Average Volume5,660 shs
Market Capitalization$1.50 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.19
Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide-based medicines in Denmark. It has a portfolio of medicines in development stage focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes glepaglutide, a long acting GLP-2 analog, which is in Phase 3 clinical trials for the treatment of short bowel syndrome; and dasiglucagon, a stable glucagon analog for the treatment of severe hypoglycemia in diabetes and congenital hyperinsulinism, as well as for use in dual-hormone artificial pancreas for automated diabetes management. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; and Beta Bionics, Inc. to initiate home-use trial of the iLet bionic pancreas with dasiglucagon for autonomous bihormonal treatment of type 1 diabetes, as well as research agreement with Orbit Discovery Ltd. and Torrey Pines Institute for Molecular Studies. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
Zealand Pharma A/S logo

MarketRank

Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 2.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZEAL
CUSIPN/A
Phone45-8877-3600
Employees329

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.20 million
Book Value$5.85 per share

Profitability

Net Income$-85,670,000.00
Net Margins-214.31%

Miscellaneous

Market Cap$1.50 billion
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable
$37.61
+0.01 (+0.03 %)
(As of 01/15/2021 08:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZEAL News and Ratings via Email

Sign-up to receive the latest news and ratings for ZEAL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zealand Pharma A/S (NASDAQ:ZEAL) Frequently Asked Questions

How has Zealand Pharma A/S's stock price been impacted by Coronavirus?

Zealand Pharma A/S's stock was trading at $28.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ZEAL stock has increased by 33.8% and is now trading at $37.61.
View which stocks have been most impacted by COVID-19
.

Is Zealand Pharma A/S a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zealand Pharma A/S stock.
View analyst ratings for Zealand Pharma A/S
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Zealand Pharma A/S?

Wall Street analysts have given Zealand Pharma A/S a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zealand Pharma A/S wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Zealand Pharma A/S's next earnings date?

Zealand Pharma A/S is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Zealand Pharma A/S
.

How were Zealand Pharma A/S's earnings last quarter?

Zealand Pharma A/S (NASDAQ:ZEAL) issued its quarterly earnings results on Tuesday, November, 17th. The company reported ($5.76) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($5.58) by $0.18. The business earned $8.88 million during the quarter, compared to the consensus estimate of $16.41 million. Zealand Pharma A/S had a negative net margin of 214.31% and a negative return on equity of 38.34%.
View Zealand Pharma A/S's earnings history
.

What price target have analysts set for ZEAL?

2 Wall Street analysts have issued 1 year price targets for Zealand Pharma A/S's shares. Their forecasts range from $42.00 to $44.00. On average, they expect Zealand Pharma A/S's stock price to reach $43.00 in the next twelve months. This suggests a possible upside of 14.3% from the stock's current price.
View analysts' price targets for Zealand Pharma A/S
or view Wall Street analyst' top-rated stocks.

Who are some of Zealand Pharma A/S's key competitors?

What other stocks do shareholders of Zealand Pharma A/S own?

Who are Zealand Pharma A/S's key executives?

Zealand Pharma A/S's management team includes the following people:
  • Dr. Emmanuel Dulac Pharm.D., PharmD, Ph.D., MBA, CEO & Pres (Age 51)
  • Mr. Matthew Donald Dallas, Sr. VP & CFO (Age 45)
  • Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Employee Representative Director (Age 67)
  • Mr. Adam Sinding Steensberg M.D., Exec. VP of R&D and Chief Medical Officer (Age 46)
  • Mr. Ivan Mourits Møller, Sr. VP of Technical Devel. & Operations (Age 48)
  • Rie Schultz Hansen, Interim Chief Scientific Officer & VP of Research
  • Lani Pollworth Morvan, Investor Relations & Communications Officer
  • Mr. Mads Kronborg, Head of Investor Relations & Communication
  • Søren Vitfell Keller, Head of Legal Affairs
  • Mr. Marino Garcia M.B.A., Sr. VP of Corp. & Bus. Devel. (Age 54)

When did Zealand Pharma A/S IPO?

(ZEAL) raised $75 million in an initial public offering on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is Zealand Pharma A/S's stock symbol?

Zealand Pharma A/S trades on the NASDAQ under the ticker symbol "ZEAL."

How do I buy shares of Zealand Pharma A/S?

Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zealand Pharma A/S's stock price today?

One share of ZEAL stock can currently be purchased for approximately $37.61.

How big of a company is Zealand Pharma A/S?

Zealand Pharma A/S has a market capitalization of $1.50 billion and generates $6.20 million in revenue each year. The company earns $-85,670,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. Zealand Pharma A/S employs 329 workers across the globe.

What is Zealand Pharma A/S's official website?

The official website for Zealand Pharma A/S is www.zealandpharma.com.

How can I contact Zealand Pharma A/S?

Zealand Pharma A/S's mailing address is SYDMARKEN 11, COPENHAGEN G7, 2860. The company can be reached via phone at 45-8877-3600 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.